Silo Pharma wins European patent for PTSD prevention therapy SPC-15
Reuters2026/08/10 12:15- Silo Pharma won a European patent for its lead PTSD candidate SPC-15, a preventative intranasal, nose-to-brain therapy targeting stress-induced psychiatric disorders.
- The EPO granted EP3952852, covering methods using selected 5-HT4 receptor agonists administered before extreme stress exposure to prevent fear or depressive-like behavior.
- The company holds an exclusive license from Columbia University for the European patent, supporting its plan to develop and commercialize SPC-15 globally.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Colgate-Palmolive (CL.US) plans to sell part of its personal care brands, with a total transaction amount possibly exceeding 1.1 billions USD.
According to sources familiar with the matter, Colgate is exploring the sale of some of its mass-market personal care brands. The company currently plans to divest only a few brands within its personal care business, and the combined sale price may exceed 1 billion dollars.
EdiliziAcrobatica announces shareholder meeting notice
Storage Giant Offers Huge Bonuses Again: Micron Awards Up to 68 Months’ Bonus
Micron Technology has announced record-breaking bonuses for its employees in Taiwan, ranging from 35 to 68 months’ salary, with a minimum cash compensation of 1.7 million New Taiwan dollars. However, the Taoyuan union, representing about two-thirds of Micron’s workers in Taiwan, has refused to accept the offer, insisting that 15% of operating profits be included in the bonus distribution and maintaining the threat of a strike.
Crypto prices
More
